
Samjin Pharmaceuticals Co., Ltd.
KRX:005500.KS
20200 (KRW) • At close July 30, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) KRW.
2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 308,349.934 | 292,128.534 | 274,031.808 | 250,070.356 | 235,164.889 | 241,926.177 | 260,016.571 | 245,271.928 | 239,312.894 | 216,511.472 | 201,305.29 | 192,006.713 | 185,702.08 | 201,756.104 | 200,410.515 | 165,388.711 | 147,996.742 | 137,112.663 |
Cost of Revenue
| 179,382.883 | 146,236.922 | 156,297.385 | 132,238.372 | 124,648.844 | 121,212.525 | 117,237.366 | 109,290.239 | 109,965.954 | 96,672.602 | 89,313.975 | 75,040.55 | 77,519.871 | 80,316.013 | 79,878.962 | 69,268.945 | 56,259.138 | 50,829.288 |
Gross Profit
| 128,967.051 | 145,891.612 | 117,734.423 | 117,831.983 | 110,516.045 | 120,713.652 | 142,779.206 | 135,981.689 | 129,346.94 | 119,838.869 | 111,991.315 | 116,966.163 | 108,182.209 | 121,440.091 | 120,531.553 | 96,119.766 | 91,737.604 | 86,283.375 |
Gross Profit Ratio
| 0.418 | 0.499 | 0.43 | 0.471 | 0.47 | 0.499 | 0.549 | 0.554 | 0.54 | 0.553 | 0.556 | 0.609 | 0.583 | 0.602 | 0.601 | 0.581 | 0.62 | 0.629 |
Reseach & Development Expenses
| 4,502.408 | 4,167.289 | 3,657.764 | 2,581.928 | 1,507.195 | 2,601.799 | 3,743.958 | 3,645.556 | 2,798.69 | 2,769.98 | 3,293.534 | 7,619.453 | 11,029.892 | 10,425.054 | 8,776.314 | 6,121.791 | 4,020.716 | 3,065.228 |
General & Administrative Expenses
| 14,923.581 | 15,149.727 | 17,144.905 | 15,053.771 | 13,955.109 | 13,444.239 | 19,703.45 | 21,630.637 | 22,218.789 | 23,472.234 | 22,623.715 | 23,454.136 | 23,426.592 | 22,116.949 | 19,700.489 | 19,731.916 | 19,173.311 | 17,506.87 |
Selling & Marketing Expenses
| 26,291.138 | 26,313.194 | 25,565.405 | 19,708.94 | 19,067.031 | 15,155.106 | 20,079.108 | 24,077.296 | 24,209.585 | 22,503.42 | 21,094.056 | 20,991.786 | 24,136.223 | 32,570.86 | 36,712.552 | 31,823.44 | 30,423.309 | 25,882.752 |
SG&A
| 41,214.719 | 41,462.921 | 42,710.31 | 34,762.711 | 33,022.14 | 28,599.345 | 39,782.558 | 45,707.933 | 46,428.374 | 45,975.654 | 43,717.771 | 44,445.922 | 47,562.815 | 54,687.809 | 56,413.041 | 51,555.356 | 49,596.62 | 43,389.622 |
Other Expenses
| 51,612.421 | 50,566.67 | 48,182.027 | 46,575.918 | 43,744.702 | 44,615.904 | 90.759 | -392.101 | -292.587 | -90.114 | -127.687 | 161.468 | -777.849 | 32,326.422 | -79.631 | -587.075 | -1,243.335 | -2,967.356 |
Operating Expenses
| 97,329.548 | 96,196.88 | 94,550.101 | 83,920.557 | 78,274.037 | 75,817.048 | 83,237.5 | 89,035.149 | 87,288.843 | 83,873.268 | 80,414.471 | 86,872.262 | 90,864.567 | 97,439.285 | 98,451.261 | 84,119.409 | 79,161.153 | 69,571.936 |
Operating Income
| 31,637.503 | 20,484.355 | 23,184.322 | 33,911.426 | 32,242.008 | 22,205.297 | 59,541.705 | 46,946.54 | 42,058.097 | 35,965.601 | 31,576.844 | 30,093.9 | 17,317.642 | 23,906.673 | 22,080.294 | 12,000.36 | 12,576.451 | 16,711.439 |
Operating Income Ratio
| 0.103 | 0.07 | 0.085 | 0.136 | 0.137 | 0.092 | 0.229 | 0.191 | 0.176 | 0.166 | 0.157 | 0.157 | 0.093 | 0.118 | 0.11 | 0.073 | 0.085 | 0.122 |
Total Other Income Expenses Net
| 13,393.858 | -4,887.71 | 2,041.929 | -402.315 | 587.62 | -23,024.975 | 508.466 | -474.115 | -3,113.897 | -1,370.882 | -1,420.693 | -1,470.592 | -2,256.783 | -2,049.833 | -6,427.532 | -2,076.34 | -2,785.644 | -4,145.14 |
Income Before Tax
| 45,031.361 | 15,596.646 | 25,226.251 | 34,911.239 | 32,829.628 | 21,871.629 | 60,050.172 | 46,472.425 | 38,944.2 | 34,594.719 | 30,156.15 | 28,623.308 | 15,060.859 | 21,856.839 | 15,652.762 | 9,924.02 | 9,790.807 | 12,566.299 |
Income Before Tax Ratio
| 0.146 | 0.053 | 0.092 | 0.14 | 0.14 | 0.09 | 0.231 | 0.189 | 0.163 | 0.16 | 0.15 | 0.149 | 0.081 | 0.108 | 0.078 | 0.06 | 0.066 | 0.092 |
Income Tax Expense
| 4,409.19 | -3,348.649 | 3,325.332 | 6,507.083 | 4,950.32 | 9,990.872 | 34,523.986 | 10,676.6 | 8,769.869 | 7,551.548 | 9,439.432 | 20,745.115 | 4,422.416 | 14,794.376 | 5,175.566 | 2,879.046 | 3,058.992 | 6,131.696 |
Net Income
| 39,232.983 | 18,908.448 | 21,893.836 | 28,404.156 | 27,879.308 | 11,880.757 | 25,526.185 | 35,795.825 | 30,174.332 | 27,043.171 | 20,716.718 | 7,878.194 | 10,638.443 | 7,062.464 | 10,477.195 | 7,044.974 | 6,731.815 | 6,434.603 |
Net Income Ratio
| 0.127 | 0.065 | 0.08 | 0.114 | 0.119 | 0.049 | 0.098 | 0.146 | 0.126 | 0.125 | 0.103 | 0.041 | 0.057 | 0.035 | 0.052 | 0.043 | 0.045 | 0.047 |
EPS
| 3,110.66 | 1,460 | 1,727.82 | 2,308.75 | 2,266.09 | 917.07 | 2,075.29 | 2,891 | 2,423 | 2,172 | 1,664 | 627 | 817 | 542 | 817 | 548.87 | 525.07 | 496.85 |
EPS Diluted
| 3,110.66 | 1,459.66 | 1,727.82 | 2,308.75 | 2,266.09 | 917.07 | 2,075.29 | 2,891 | 2,423 | 2,172 | 1,664 | 627 | 817 | 542 | 817 | 548.87 | 525.07 | 496.85 |
EBITDA
| 65,920.229 | 36,595.366 | 33,000.377 | 41,271.89 | 39,361.652 | 27,578.304 | 66,342.312 | 53,251.57 | 46,293.204 | 42,048.009 | 37,609.79 | 35,901.052 | 20,873.787 | 27,481.352 | 26,271.722 | 15,263.796 | 14,840.584 | 16,848.218 |
EBITDA Ratio
| 0.214 | 0.125 | 0.12 | 0.165 | 0.167 | 0.114 | 0.255 | 0.217 | 0.193 | 0.194 | 0.187 | 0.187 | 0.112 | 0.136 | 0.131 | 0.092 | 0.1 | 0.123 |